
Consensus guidelines have recommended that SGLT2 inhibitors be avoided in cases of serious illness and suggest they are not recommended for routine in‐hospital use. However, recent data suggest potential beneficial effects of SGLT2 inhibitors in the setting of acute illness with COVID‐19 with no increase in adverse events and low rates of DKA, which were non‐severe. Given the low rates of DKA in cardiovascular outcome trials and hospitalized type 2 diabetes patients, the potential for SGLT2 inhibitors not being re‐initiated following discharge and their cardiovascular and kidney benefits, the practice of routine “sick day” guidance should be re‐examined based on current evidence with a call for further research in this area.
Like
Save
Share